[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "Based on the patient's presentation, her low CD4+ T-lymphocyte count, and the imaging and cerebrospinal fluid findings, the most likely diagnosis is HIV-associated primary central nervous system lymphoma (PCNSL). PCNSL is a type of non-Hodgkin lymphoma that occurs in immunocompromised individuals, particularly those with advanced HIV infection. It typically presents with symptoms such as headaches, confusion, and ataxia, and often involves the corpus callosum. The presence of Epstein-Barr virus DNA in the cerebrospinal fluid is also consistent with PCNSL, as the virus is frequently found in these tumors. Treatment typically involves chemotherapy and radiation therapy, with the goal of improving symptoms and prolonging survival.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "The medication that acts on the gp41 subunit of the HIV envelope glycoprotein is Enfuvirtide.",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A mother with HIV has given birth to a healthy boy 2 days ago. She takes her antiretroviral medication regularly and is compliant with the therapy. Before being discharged, her doctor explains that she cannot breastfeed the child since there is a risk of infection through breastfeeding and stresses that the child can benefit from formula feeding. The physician stresses the importance of not overheating the formula since Vitamin C may be inactivated by overheating. What molecular process could be impaired if the mother boiled the formula longer than needed?",
    "answer": "The molecular process that could be impaired if the mother boiled the formula longer than needed is denaturation of proteins. Proteins in the formula could be denatured by overheating, which can lead to a loss of their functional properties, including their ability to provide essential nutrients to the child.",
    "true_answer": "If the formula is boiled longer than needed, resulting in the inactivation of Vitamin C, then collagen synthesis could be impaired."
  },
  {
    "question": "A 35-year-old woman presents to a physician\u2019s office for a follow-up visit. She recently underwent a complete physical examination with routine laboratory tests. She also had a Pap smear and testing for sexually transmitted diseases. Since her divorce 2 years ago, she had sexual encounters with random men at bars or social events and frequently did not use any form of protection during sexual intercourse. She was shown to be positive for the human immunodeficiency virus (HIV). Combination anti-retroviral treatment is initiated including zidovudine, didanosine, and efavirenz. One week later, she is rushed to the hospital where she is diagnosed with acute pancreatitis. What precautions in her medication will be required after pancreatitis resolves with treatment?",
    "answer": "The patient will need to be switched off didanosine, as it is associated with a higher risk of pancreatitis. The patient can continue on zidovudine and efavirenz, but a different medication will need to be added to complete her combination anti-retroviral therapy regimen.",
    "true_answer": "After resolving pancreatitis, didanosine should be replaced with lamivudine to avoid recurrence."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "The most likely target of the antibody the physician scientist is designing would be the gp120 protein, as it is the primary envelope protein responsible for binding to host cells and initiating infection.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "The presence of septate hyphae with acute angle branching is characteristic of Aspergillus species. Given the patient's HIV status and the presence of a fibrocavitary lesion in the lung, the most likely diagnosis is chronic pulmonary aspergillosis. Treatment may involve antifungal medications such as voriconazole or itraconazole.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "The patient is at greatest risk of developing neutropenia due to the addition of valganciclovir to his current medication regimen. Valganciclovir, an antiviral medication, can cause myelosuppression, a decrease in the production of blood cells by the bone marrow, which can result in neutropenia, a decrease in the number of neutrophils (a type of white blood cell). Additionally, zidovudine, a component of the patient's current antiretroviral therapy, can also cause myelosuppression, and the combination of these two drugs may increase the risk of neutropenia.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "The most appropriate diagnostic test for this patient's baby would be an HIV DNA PCR test, which can detect the presence of HIV genetic material in the baby's blood. This test is recommended in newborns born to HIV-positive mothers because it can detect virus infection as early as 2-4 weeks after birth, even before antibodies are produced. The test should be performed at birth, 6 weeks, and 6 months of age. If the test is negative at 6 months of age, it is highly likely that the baby is not infected.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "The physician should explain to the patient the risks of not disclosing his diagnosis to his wife and the potential consequences for her health. The physician can offer to facilitate a conversation between the couple, with the patient's consent, to share the diagnosis and discuss options for protecting his wife's health. However, the physician cannot disclose the patient's diagnosis to his wife without his consent, as this would violate confidentiality. The physician should also remind the patient of his legal obligations to report his diagnosis to the health department, which will notify any at-risk sexual partners. It is also important to note that the physician has a duty to protect the patient's confidentiality while also protecting potential third-party harm. In some jurisdictions, the physician may have a legal obligation to report the patient's diagnosis to the health department, which may notify the wife if the patient has not already done so.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old HIV-positive male presents to the ER with a 4-day history of headaches and nuchal rigidity. A lumbar puncture shows an increase in CSF protein and a decrease in CSF glucose. When stained with India ink, light microscopy of the patient\u2019s CSF reveals encapsulated yeast with narrow-based buds. Assuming a single pathogenic organism is responsible for this patient\u2019s symptoms, what diagnostic test results would also be expected in this patient?",
    "answer": "The patient's symptoms and CSF findings, along with the India ink staining results, suggest cryptococcal meningitis caused by Cryptococcus neoformans. Additional diagnostic tests such as a positive cryptococcal antigen test in the CSF or blood and a positive culture of Cryptococcus neoformans from the CSF would also be expected in this patient.",
    "true_answer": "A latex agglutination test specific for Cryptococcal meningitis would also be expected in this patient."
  },
  {
    "question": " What would be the best methodological approach to study microRNAs as therapeutic targets in HIV patients?",
    "answer": "The best methodological approach to study microRNAs as therapeutic targets in HIV patients would involve a combination of in vitro and in vivo studies. In vitro studies could involve the use of cell lines and primary cells to identify and validate specific microRNAs that are involved in HIV replication, latency, and pathogenesis. These studies could also assess the effect of microRNA mimics and inhibitors on HIV replication and latency. In vivo studies could involve the use of animal models to evaluate the efficacy and safety of microRNA-based therapies. The use of humanized mice models could be particularly useful for studying HIV infection and replication. Clinical trials would be necessary to evaluate the safety and efficacy of microRNA-based therapies in HIV patients. Overall, a multidisciplinary approach involving virology, molecular biology, biochemistry, and pharmacology would be necessary to study microRNAs as therapeutic targets in HIV patients.",
    "true_answer": "To study microRNAs as therapeutic targets in HIV patients, the best methodological approach would likely include a combination of in vitro experiments, in vivo animal models, and clinical trials . Initial in vitro experiments would involve the use of HIV-infected cell lines or primary cells to study the function and expression of specific microRNAs in relation to HIV replication and pathogenesis . This research would provide insights into the potential roles of microRNAs in HIV infection and help identify candidate microRNAs for therapeutic targeting . Next, in vivo animal models, such as humanized mice, should be employed to study the effects of modulating specific microRNAs on HIV infection and disease progression . These models would help evaluate the safety and efficacy of potential microRNA-based therapies, as well as investigate the potential for off-target effects and immunogenicity . Techniques such as delivery of microRNA mimics or antagomirs, viral vector-mediated overexpression or knockdown, and CRISPR-Cas9 editing can be used to manipulate microRNA expression in these models  . Finally, clinical trials should be conducted to validate the safety, efficacy, and tolerability of potential microRNA-based therapies in HIV patients . These trials would involve the enrollment of HIV-positive patients to receive the experimental treatment(s) under controlled conditions, with rigorous monitoring of viral load, treatment-related adverse events, immune function, and other relevant parameters . The results of these clinical trials would be instrumental in determining the clinical feasibility of microRNA-based therapies for treating HIV infections ."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "There is growing evidence that DNA methylation, which is an epigenetic modification of DNA, plays a role in the regulation of HIV-1 expression in infected cells. In particular, DNA methylation has been shown to contribute to the establishment and maintenance of HIV-1 latency in resting CD4+ T cells. Methylation of the HIV-1 promoter region, which is a key regulatory region in the virus genome, has been implicated in the silencing of viral gene expression and the establishment of latency. Additionally, DNA methylation has also been linked to the reactivation of latent HIV-1, as demethylation of the HIV-1 promoter region has been shown to promote viral gene expression and the release of infectious virus. In patients with active HIV-1 infection, there is also evidence to suggest that DNA methylation may play a role in the regulation of viral gene expression and the modulation of immune responses. However, the exact mechanisms by which DNA methylation contributes to HIV-1 pathogenesis are not yet fully understood and require further investigation.",
    "true_answer": "I searched for your question and found some relevant results. According to these results, **DNA methylation** is a possible mechanism that regulates the **latency** and **reactivation** of **HIV-1 provirus** in infected cells  . However, the **methylation profiles** of HIV-1 proviral DNA may vary depending on the **disease progression**, **antiretroviral therapy**, and **cell type** of the patients ."
  }
]